Empagliflozin as a Novel Therapy in Refractory Ascites
Status:
Recruiting
Trial end date:
2022-10-05
Target enrollment:
Participant gender:
Summary
The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of
empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard
care for refractory ascites in patients with liver cirrhosis